Suppr超能文献

接受红细胞和晶体液大量输血患者的实验室止血异常情况。

Laboratory hemostatic abnormalities in massively transfused patients given red blood cells and crystalloid.

作者信息

Leslie S D, Toy P T

机构信息

Blood Bank San Francisco General Hospital, California 94110.

出版信息

Am J Clin Pathol. 1991 Dec;96(6):770-3. doi: 10.1093/ajcp/96.6.770.

Abstract

Most of the literature on massive transfusion concerns whole blood replacement, whereas clinically, packed red blood cells are commonly given. To determine when hemostatic abnormalities occur in patients resuscitated primarily with packed red blood cells and crystalloid, the cases of 39 consecutive patients who were transfused with 10 or more red blood cell units of any kind within 24 hours were reviewed. After transfusion with 20 or more units of red blood cell products of any kind (packed red blood cells, cell-saver units, or whole blood), 75% (3 of 4) of patients had platelet counts less than 50 x 10(9)/L, compared to 0 of 29 patients given less than 20 units (P less than 0.001). After transfusion of 12 units of relatively plasma-free red blood cell products (packed red blood cells or cell-saver units), 100% (8 of 8) of patients had prothrombin time prolonged by more than 1.5 times mid-range of normal, compared to 36% (5 of 14) of patients given less than 12 units (P = 0.012). These data confirm that patients massively transfused with red blood cells of any kind develop significant thrombocytopenia after 20 units. Importantly, probably clinically significant prothrombin time and partial thromboplastin time prolongations occurred consistently after transfusion of 12 units of relatively plasma-free red blood cells in unselected patients at an urban trauma hospital. These data suggest that coagulation factor replacement is necessary in patients who receive 12 or more units of packed red blood cells or cell-saver blood, and platelet replacement is necessary in patients who receive 20 or more units of any red blood cell product. A prospective study is needed to determine whether the expected abnormal clinical bleeding indeed occurs in patients with such laboratory coagulation abnormalities and to determine when plasma transfusion is indicated in patients massively transfused with red blood cells.

摘要

大多数关于大量输血的文献关注的是全血置换,而在临床上,常用的是浓缩红细胞。为了确定主要接受浓缩红细胞和晶体液复苏的患者何时出现止血异常,回顾了39例在24小时内输注10个或更多单位任何类型红细胞的连续患者的病例。在输注20个或更多单位任何类型的红细胞制品(浓缩红细胞、自体血回输单位或全血)后,75%(4例中的3例)患者的血小板计数低于50×10⁹/L,而输注少于20单位的29例患者中这一比例为0(P<0.001)。在输注12单位相对无血浆的红细胞制品(浓缩红细胞或自体血回输单位)后,100%(8例中的8例)患者的凝血酶原时间延长超过正常范围中位数的1.5倍,而输注少于12单位的患者中这一比例为36%(14例中的5例)(P = 0.012)。这些数据证实,大量输注任何类型红细胞的患者在输注20单位后会出现显著的血小板减少。重要的是,在一家城市创伤医院的未选择患者中,输注12单位相对无血浆的红细胞后,凝血酶原时间和部分凝血活酶时间延长可能具有临床意义,且这种情况持续出现。这些数据表明,接受12个或更多单位浓缩红细胞或自体血回输的患者需要进行凝血因子替代,而接受20个或更多单位任何红细胞制品的患者需要进行血小板替代。需要进行一项前瞻性研究,以确定此类实验室凝血异常的患者是否确实会出现预期的临床异常出血,并确定大量输注红细胞的患者何时需要输注血浆。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验